Attached are KEI’s January 30, 2015 comments on the India IP Policy.
/wp-content/uploads/KEI_30Jan2015_Comments_India_IPR_Policy.pdf
This is how the comments begin:
Knowledge Ecology International (KEI) has reviewed the document entitled “National IPR Policy” prepared by the IPR Think Tank. The document is surprisingly lacking in several key areas. In particular:
Attached are:
1. The SEPTA the law suit.
2. A pessimistic 2011 OECD working paper on the weak competition remedies for excessive pricing in the United States.
3. A 2012 report on a 2011 OECD policy roundtable on excessive pricing
Below is a cleaned up version of the transcript, from my rambling intervention for KEI on the broadcasting treaty definitions.
Thank you, Mr. Chairman. My comments would be initially on the definitions.It is our position that it’s more appropriate to provide protection for free services that are traditionally provided by radio and television and less appropriate for pay services,
Broadcasters make sweeping demands on scope and rights in new WIPO treaty
To understand the negotiations this week at the WIPO SCCR 29, it is helpful to review an April 2014 document, endorsed by several broadcasting organizations.
The attached document* is a joint statement by 12 broadcasting organizations, on “THE OBJECTIVES, SPECIFIC SCOPE AND OBJECT OF THE PROPOSED WIPO BROADCASTERS’ TREATY”.
The new Medicines Patent Pool license with AbbVie: good news for children living with HIV
The Medicines Patent Pool (MPP) has signed a new license with AbbVie, to expand access to pediatric formulations of lopinavir (LPV) and ritonavir (r). The details of the licenses are available here:
NIH rulemaking on transparency of clinical trials
The NIH has a notice about a proposed rule that “clarifies and expands requirements for the submission of clinical trial registration and results information to the ClinicalTrials.gov database.” Comments are due on or before February 19, 2015. We may ask the NIH to consider expanding the trials registry to include more information on the economics of clinical trials.
Here is a link to the Regulations.Gov docket for the proposed rule:
http://www.regulations.gov/#!documentDetail;D=NIH-2011-0003-0003 Continue Reading
UACT sends letter to Tufts President, Chairman of Trustees, asking questions about R&D cost study
On November 24, 2014. the Union for Affordable Cancer Treatment (UACT) sent a letter to Anthony P. Monaco, Office of the President, Tufts University, with copies to Michael Baenen, the Tufts Chief of Staff, and Peter Dolan, Chairman of the Board of Trustees for Tufts University, regarding the Tufts University press conference to announce an estimate of $2.6 billion as the R&D costs for new drugs. Continue Reading
KEI comment on the new Tufts Study on Drug Development Costs
The Tuft Center for Study of Drug Development (CSDD) has just concluded a press conference, and issued a press release about their new study of drug development costs. The key number is $2.558 billion.
What to look for in the new Tufts study on drug development costs. 10 issues.
When the new Tufts study on the costs of R&D for development of a new drug is released Tuesday at 10AM, here are 10 things to look for:
Research note on oncology drugs, including trial size and orphan drug status
We will be sharing some data on 2005 to 2014 oncology approvals, including the size of the trials cited in the medical review, and the orphan status.
The spreadsheet we are working on updating is published here: